FDA OKs New Once-Daily Asthma Treatment – WebMD


Bidness Etc

FDA OKs New Once-Daily Asthma Treatment
WebMD
Arnuity Ellipta has been tested in more than 3,600 people with asthma, the company says in a statement. The most common side effects (reported in at least 5% of people) were upper respiratory tract infection, common cold, headache, and bronchitis.
GlaxoSmithKline grabs FDA approval for its latest asthma treatmentFierceBiotech
GSK's Asthma Treatment Gets FDA ApprovalBidness Etc
FDA OKs New Maintenance Asthma Treatment Arnuity ElliptaMedscape
Philadelphia Business Journal (blog) –Pharmaceutical Business Review –Healio
all 29 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.